行情

IMGN

IMGN

ImmunoGen
NASDAQ

实时行情|Nasdaq Last Sale

3.700
+0.160
+4.52%
已收盘, 17:52 03/27 EDT
开盘
3.360
昨收
3.540
最高
3.880
最低
3.340
成交量
290.81万
成交额
--
52周最高
7.07
52周最低
1.760
市值
6.45亿
市盈率(TTM)
-5.2602
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测IMGN价格均价为6.70,最高价位9.00,最低价为4.000。

EPS

IMGN 新闻

更多
  • ImmunoGen: Tremendous Value In Your Turnaround Stock
  • Seeking Alpha - Article · 4天前
  • Why Is ImmunoGen (IMGN) Down 45.5% Since Last Earnings Report?
  • Zacks · 03/15 16:30
  • Edited Transcript of IMGN earnings conference call or presentation 14-Feb-20 1:00pm GMT
  • Thomson Reuters StreetEvents · 02/21 10:44
  • ImmunoGen: A Potential Turnaround Story For 2020
  • Seeking Alpha - Article · 02/21 07:26

所属板块

生物技术和医学研究
-2.43%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

IMGN 简况

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.
展开

微牛提供ImmunoGen, Inc.(NASDAQ-IMGN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的IMGN股票新闻,以帮助您做出投资决策。